(CMPX) Compass Therapeutics, Inc. Business Model Canvas Research

Compass Therapeutics, Inc. relies on regulatory advisors and bioanalytical labs to shape FDA-facing strategy and run assay work for antibody trials. Bioanalytical partners measure pharmacokinetics, biomarkers, and immune responses, which are core readouts when testing biologics in human studies.

• FDA strategy support
• PK and biomarker testing
• Immune response readouts
• Needed for antibody trials

Compass Therapeutics, Inc. (Nasdaq: CMPX) depends on capital markets investors to fund R and D through equity financing, because its clinical work can take years before sales arrive. Institutional holders matter most here, since they help support long development timelines and reduce pressure for near-term cash flow.

• Public equity funds R and D.
• CMPX trades on Nasdaq.
• Institutions back long trials.

Compass Therapeutics, Inc. runs chemistry, manufacturing, and controls for antibody supply to keep process consistency, quality, and release testing tight. Reliable supply is critical for every clinical study, and the company’s 2025 work centers on avoiding batch drift, failed release, and trial delays.

• Process consistency
• Quality control
• Release testing
• Clinical supply continuity

Compass Therapeutics, Inc. runs a tight regulatory and safety process for its oncology trials: it files safety updates, protocol amendments, and adverse-event reports, while continuously checking risk-benefit signals. As a pre-commercial Company with no product revenue, that discipline is central to keeping studies compliant and moving.

• Files safety updates and amendments
• Tracks adverse events closely
• Monitors risk-benefit signals
• Supports oncology trial compliance

Compass Therapeutics, Inc. relies on a small but highly specialized scientific and clinical team to drive target discovery, trial design, and partner management. In 2025, that human capital stayed central because the company remained pre-commercial, so talent quality matters more than scale.

• Experienced scientists move programs forward
• Clinicians shape trial design and execution
• Drug developers support partner work
• Specialized talent is a key resource

Compass Therapeutics, Inc. is based in Boston, Massachusetts, giving it direct access to one of the strongest U.S. biotech talent pools and a dense cluster of investors, labs, and research partners. Its Nasdaq listing under CMPX also gives the Company a public equity funding path, which can support hiring and capital needs while keeping the brand visible to markets.

• Boston location supports recruiting.
• Nasdaq CMPX supports equity financing.
• Market access improves investor visibility.

CTX-8371 is a bispecific PD-1/PD-L1 inhibitor that targets a core cancer immune-evasion path. The pitch is simple: block both checkpoints at once, which may help beat resistance seen with single-target PD-1 or PD-L1 drugs.

That matters in a class led by massive sellers like Keytruda, which reported $29.5 billion in 2024 sales, showing how much value sits in checkpoint blockade. For Compass Therapeutics, Inc., CTX-8371 aims to win by broader pathway coverage, not just another single-target copy.

• Dual PD-1/PD-L1 blockade
• May reduce escape resistance
• Targets a proven high-value class

Compass Therapeutics, Inc.’s assets are built for combination use with other oncology drugs, which matters because solid tumors make up about 90% of adult cancers and often need multi-drug regimens. If combos lift response rates, they can broaden use across lines of therapy and expand the market.

• Built for oncology combinations
• Can raise response rates
• Fits solid tumor development

In FY2025, Compass Therapeutics, Inc. stayed a clinical-stage biotech, so partner and sponsor communication is usually milestone based, with updates tied to trial readouts, governance calls, and budget checks. Clear, frequent reporting matters because biotech deals depend on transparency, and tighter oversight cuts execution risk.

• Milestone-led updates
• Governance over ad hoc contact
• Transparency lowers risk

Compass Therapeutics, Inc. keeps investor relations reporting continuous and disclosure-led through quarterly earnings calls and SEC filings, including its Form 10-K and Form 10-Q. This matters because biotech timelines are long and capital access depends on clear updates on cash, trial progress, and risk.

• Quarterly earnings calls
• SEC filings drive disclosure
• Supports long-cycle funding

For a public drug developer, this channel is the main trust link with investors, analysts, and lenders, helping Compass Therapeutics, Inc. stay financed while programs move through multi-year development.

Compass Therapeutics, Inc. reaches investors through earnings releases, webcast calls, and SEC filings, with Nasdaq listing giving it daily market visibility. Capital-markets outreach is a key financing channel, since biotech firms rely on clear updates on pipeline progress, cash use, and funding needs.

• Earnings releases and webcasts
• SEC filings and investor updates
• Nasdaq visibility for broad reach
• Capital markets support financing

Compass Therapeutics, Inc. uses direct corporate outreach and licensing talks to reach biopharma partners and strategic investors, a channel that can bring non-dilutive capital and co-development support. This matters because partnering deals in biotech often fund late-stage work without issuing new shares, helping preserve value for existing holders.

• Direct outreach to biopharma
• Licensing talks for assets
• Targets strategic investors
• Supports non-dilutive funding

Biopharma licensing partners are key for Compass Therapeutics, Inc.: they can pay upfront fees, fund development, and add future royalties, creating near-term non-product cash while the pipeline is still clinical-stage. In biotech deals, upfronts often run $10 million-$50 million, with milestones that can exceed $100 million, so each partner can matter more than early sales.

• Upfront cash can fund trials
• Milestones reduce dilution risk
• Royalties add later upside

Clinical investigators and research networks are key customers and partners for Compass Therapeutics, Inc.; they shape study design, select patients, and generate the data that proves early efficacy. Strong site networks matter because they can shorten enrollment and move a program to proof of concept faster, which is critical in oncology where rapid readouts drive capital use.

• Influence trial design and sites
• Drive patient enrollment and data quality
• Speed proof-of-concept readouts

Compass Therapeutics, Inc. must keep paying for SEC filings, outside counsel, and patent upkeep to protect its pipeline and stay compliant. In 2025, USPTO patent maintenance fees were $2,000, $4,000, and $8,000 at 3.5, 7.5, and 11.5 years for large entities, with biotech legal and regulatory spend staying structurally high.

• Filings and counsel are recurring costs
• Patent fees protect IP value
• Biotech legal spend stays elevated

Compass Therapeutics, Inc. carries general and administrative overhead from public-company reporting, finance, legal, and executive work, and Nasdaq listing keeps compliance costs recurring. This cost line stays smaller than research and development, but it is still material because it funds SEC filings, audits, board oversight, and corporate support.

• Public-company reporting drives fixed costs
• Nasdaq adds compliance expense
• Office and corporate costs stay material

As of FY2025, Compass Therapeutics, Inc. had no approved product and no direct product-sales revenue, so "future product sales" is a zero-to-meaningful swing stream. If a candidate clears approval, direct sales can become the highest-margin revenue line, but only after clinical success and payer access.

• FY2025 product sales: $0
• Approval unlocks direct sales
• Best long-term margin profile
• Depends on market access

Compass Therapeutics, Inc. can use royalties on net sales as a low-capital biotech revenue stream: licensing deals often pay a % of future sales, so the Company can earn upside without funding full launch costs. In biotech, royalty rates often sit in the low single digits to mid-teens, while Compass Therapeutics reported no product sales in recent filings, so this layer matters only if partnered assets reach market.

• Low-cost upside on future sales
• Common in biotech licenses
• Depends on partner commercialization